Breaking News Instant updates and real-time market news.

PRQR

ProQR Therapeutics

$5.81

-0.37 (-5.99%)

14:55
10/10/19
10/10
14:55
10/10/19
14:55

ProQR Therapeutics price target raised to $40 from $34 at Citi

Citi analyst Yigal Nochomovitz raised his price target on ProQR Therapeutics to $40 from $34, stating that he disagree's with the market's initial take on the company's updated data on sepofarsen. Given his view that the 12-month data validate the treatment benefits observed at 3 months, Nochomovitz increased his odds on the success for sepofarsen in patients with Leber's congenital amaurosis 10 to 70% from 50% and keeps his Buy rating on the stock. In afternoon trading, ProQR shares are down 26c, or 4%, to $5.95.

  • 10

    Oct

  • 11

    Oct

PRQR ProQR Therapeutics
$5.81

-0.37 (-5.99%)

01/14/19
CANT
01/14/19
NO CHANGE
CANT
Cantor highlights BioMarin, ProQR after JPMorgan Healthcare Conference
Cantor Fitzgerald analyst Eliana Merle found BioMarin's (BMRN) gene therapy platform advances and "improved risk-reward" for ProQR Therapeutics' (PRQR) USH2A program ahead of key data mid-2019 as most notable from the JPMorgan Healthcare Conference. The analyst left feeling more confident about BioMarin's gene therapy platform, which she thinks could positively surprise over the next 12-24 months as new programs enter the clinic. Further, she thinks the safety events in question at this point are likely overdone in ProQR shares following the 15% selloff since the conference. Merle now sees an "even more" favorable risk/reward into the company's mid-2019 proof-of-concept readout from a separate program.
02/20/19
SBSH
02/20/19
NO CHANGE
SBSH
Buy
Citi opens 90-day catalyst watch on ProQR Therapeutics
Citi analyst Yigal Nochomovitz opened a 90-day catalyst watch on ProQR Therapeutics in anticipation of the interim Phase 1/2 Wings data for QR-313 in dystrophic epidermolysis bullosa. On positive data, or evidence of exon skipping in biopsies and evidence of skin lesion/blister resolution, the analyst sees the stock up 15%-25%. On negative data, he sees downside of 10%-15%. Nochomovitz has a Buy rating on ProQR Therapeutics.
03/27/19
CANT
03/27/19
NO CHANGE
Target $40
CANT
Overweight
ProQR Therapeutics spin-out 'smart, but not surprising,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle thinks ProQR Therapeutics' spin-out of its dystrophic epidermolysis bullosa program is a "smart, but not surprising," strategic move. Given that the company has communicated it wants to focus on its ophthalmology programs, investors are unlikely to find this announcement about the skin program spin-out surprising, Merle tells investors in a research note. The analyst keeps an Overweight rating on ProQR Therapeutics with a $40 price target.
10/09/19
CANT
10/09/19
NO CHANGE
Target $40
CANT
Overweight
ProQR shares could more than double on tomorrow's data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on ProQR Therapeutics with a $40 price target ahead of tomorrow's data update on lead program QR-110, which is in development for LCA10, a rare genetic form of blindness. Investors view ProQR and QR-110 as a "show-me story," but these data could lift a "significant overhang" around platform safety and serve as a "key piece of clinical de-risking" for QR-110's Phase 2/3 trial under way, Merle tells investors in a research note partially titled "A double by this time tomorrow?". The analyst thinks the stock could trade up 50%-150% tomorrow versus downside to its cash position of ~$2 per share, or ~65%.

TODAY'S FREE FLY STORIES

TEUM

Pareteum

$0.74

-0.0948 (-11.42%)

16:40
10/21/19
10/21
16:40
10/21/19
16:40
Hot Stocks
Pareteum to restate previously issued financial statements »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CDNS

Cadence Design

$66.67

1.07 (1.63%)

16:38
10/21/19
10/21
16:38
10/21/19
16:38
Hot Stocks
Breaking Hot Stocks news story on Cadence Design »

Cadence Design up 4.5% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 06

    Nov

  • 19

    Nov

MIST

Milestone Pharmaceuticals

$21.60

2.1 (10.77%)

16:38
10/21/19
10/21
16:38
10/21/19
16:38
Conference/Events
Milestone Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:37
10/21/19
10/21
16:37
10/21/19
16:37
Hot Stocks
Breaking Hot Stocks news story on Celanese »

Celanese down 2.8% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:36
10/21/19
10/21
16:36
10/21/19
16:36
Earnings
Celanese sees FY20 EPS $11-$12 , consensus $11.25 »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HMST

HomeStreet

$28.66

0.27 (0.95%)

16:36
10/21/19
10/21
16:36
10/21/19
16:36
Hot Stocks
HomeStreet board approves additional share buyback of up to $25M »

HomeStreet said its board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GME

GameStop

$5.93

-0.02 (-0.34%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Conference/Events
GameStop management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HSTM

HealthStream

$26.33

0.13 (0.50%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Earnings
HealthStream sees FY19 revenue $252M-$256M, consensus $255.46M »

Sees FY19 Adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Earnings
Celanese cuts FY19 EPS view to $9.60-$9.80 from 'see path to $10.50' 

Consensus $10.14.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HMST

HomeStreet

$28.66

0.27 (0.95%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Earnings
HomeStreet reports Q3 EPS 54c, consensus 33c »

"Homestreet's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:34
10/21/19
10/21
16:34
10/21/19
16:34
Hot Stocks
Celanese says market conditions unlikely to improve in 2019 »

The company's says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

OSB

Norbord

$26.75

0.36 (1.36%)

16:33
10/21/19
10/21
16:33
10/21/19
16:33
Hot Stocks
Norbord to indefinitely curtail production on Line 1 at Cordele OSB mill »

Nobord announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSTM

HealthStream

$26.33

0.13 (0.50%)

16:33
10/21/19
10/21
16:33
10/21/19
16:33
Earnings
HealthStream reports Q3 EPS 11c, consensus 6c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UGI

UGI Corporation

$48.25

0.07 (0.15%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Conference/Events
UGI Corporation management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 12

    Nov

BXS

BancorpSouth

$29.66

0.17 (0.58%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Earnings
BancorpSouth reports Q3 net operating EPS 69c, consensus 61c »

Net interest margin -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

, AMTD

TD Ameritrade

$37.64

0.85 (2.31%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Hot Stocks
TD Bank comments on expected impact of TD Ameritrade Q4 earnings »

TD Bank Group (TD)…

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

AMTD

TD Ameritrade

$37.64

0.85 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Oct

SECO

Seeco Holding

$6.15

0.2 (3.36%)

16:31
10/21/19
10/21
16:31
10/21/19
16:31
Conference/Events
Seeco Holding management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:31
10/21/19
10/21
16:31
10/21/19
16:31
Earnings
Celanese reports Q3 adjusted EPS $2.53, consensus $2.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

OBE

Obsidian Energy

$0.70

(0.00%)

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Hot Stocks
Obsidian Energy CFO David Hendry resigns »

Obsidian Energy said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWAV

ShockWave Medical

$33.98

1.68 (5.20%)

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Options
Preliminary option volume of 16.2M today »

Preliminary option volume…

TCMD

Tactile Systems

$46.66

-0.42 (-0.89%)

16:29
10/21/19
10/21
16:29
10/21/19
16:29
Initiation
Tactile Systems initiated  »

Tactile Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

SAGE

Sage Therapeutics

$140.90

0.9 (0.64%)

16:29
10/21/19
10/21
16:29
10/21/19
16:29
Conference/Events
Sage Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 12

    Nov

NVRO

Nevro

$85.85

0.88 (1.04%)

16:27
10/21/19
10/21
16:27
10/21/19
16:27
Initiation
Nevro initiated  »

Oppenheimer starts Nevro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

WSFS

WSFS Financial

$44.14

0.02 (0.05%)

16:26
10/21/19
10/21
16:26
10/21/19
16:26
Earnings
WSFS Financial reports Q3 EPS 98c, consensus 87c »

Net interest income in 3Q…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.